What is SouthernBiotech?
Established in 1982, SouthernBiotech has cultivated a robust reputation as a premier provider of high-quality antibodies essential for advanced research applications. The company operates at the intersection of drug development and discovery studies, offering a comprehensive portfolio that includes primary and secondary antibodies, as well as specialized immunoreagents. Their commitment to in-house production and rigorous validation protocols ensures that researchers receive reliable, high-performance tools. By maintaining a focus on customizable solutions and responsive technical support, SouthernBiotech has solidified its position as a critical partner for academic and commercial laboratories engaged in complex biological investigations.
How much funding has SouthernBiotech raised?
SouthernBiotech has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in SouthernBiotech
PPP
Public-Private Partnership
What's next for SouthernBiotech?
With the successful completion of this late-stage financing round, SouthernBiotech is poised to accelerate its strategic growth initiatives. The influx of capital will likely be directed toward scaling production capabilities to meet the rising demand for high-fidelity diagnostic reagents and expanding their custom service offerings. As the biotechnology sector continues to prioritize precision and reliability in research tools, SouthernBiotech's long-standing expertise provides a competitive moat. Future efforts will likely focus on integrating advanced manufacturing technologies to optimize delivery timelines and further enhancing their product validation processes to maintain industry-leading standards in the evolving landscape of drug discovery and clinical diagnostics.
See full SouthernBiotech company page
